The labeling provided to health professionals (but not to the general public) may contain the following additional indications.
For products containing cyclizine hydrochloride, dimenhydrinate, and diphenhydramine hydrochloride identified in § 336.10 (a), (b), and (c). “For the treatment of vertigo of motion sickness.”
For products containing meclizine hydrochloride identified in § 336.10(d). “For the treatment of vertigo.”